BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang L, Ge N, Chen Y, Xie X, Yin X, Gan Y, Zhang B, Zhang J, Chen R, Wang Y, Ye S, Ren Z. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patients. Med Oncol 2015;32. [DOI: 10.1007/s12032-015-0532-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Xie XY, Chen Y, Ge NL, Chen RX, Gan YH, Zhang BH, Wang YH, Ren ZG. Hepatitis B surface antigen predicts recurrence after radiofrequency ablation in patients with low hepatitis B virus loads. Medicine (Baltimore) 2017;96:e9377. [PMID: 29384914 DOI: 10.1097/MD.0000000000009377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Cao G, Liu Y, Li L, Zhao X, Liu R, Liu J, Liu J, Cao H. A Comparison of Adverse Events Among Radiofrequency Ablation, Conventional Transarterial Chemoembolization (TACE) and Drug-Eluting Bead TACE in Treating Hepatocellular Carcinoma Patients. Cancer Manag Res 2021;13:5373-82. [PMID: 34262345 DOI: 10.2147/CMAR.S308097] [Reference Citation Analysis]
3 Zhang W, Jiang L, Yan L, Yang J, Li B, Wen T, Zeng Y, Wang W, Xu M. Radiofrequency ablation for HCC patients with multifocal tumours meeting the Milan criteria: A single-centre experience. Digestive and Liver Disease 2016;48:1485-91. [DOI: 10.1016/j.dld.2016.07.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
4 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
5 Zhou Y, Ding J, Qin Z, Wang Y, Zhang J, Jia K, Wang Y, Zhou H, Wang F, Jing X. Predicting the survival rate of patients with hepatocellular carcinoma after thermal ablation by nomograms. Ann Transl Med 2020;8:1159. [PMID: 33241008 DOI: 10.21037/atm-20-6116] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Hijazi H, Campeau MP, Roberge D, Donath D, Lapointe R, Vandenbroucke-Menu F, Taussky D, Boudam K, Chan G, Bujold A, Delouya G. Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience. Cureus 2016;8:e935. [PMID: 28123916 DOI: 10.7759/cureus.935] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
7 Sucandy I, Cheek S, Golas BJ, Tsung A, Geller DA, Marsh JW. Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors. HPB (Oxford). 2016;18:756-763. [PMID: 27593593 DOI: 10.1016/j.hpb.2016.06.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
8 Yang Y, Xin Y, Ye F, Liu N, Zhang X, Wang Y, Li X, Fan Q, Zhou X, Chen Y. Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors. Int J Hyperthermia 2021;38:437-46. [PMID: 33724137 DOI: 10.1080/02656736.2020.1849828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wake T, Tateishi R, Nakagomi R, Fujiwara N, Kinoshita MN, Nakatsuka T, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Tanaka Y, Shiina S, Koike K. Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery. Hepatol Res 2018;49:453-61. [DOI: 10.1111/hepr.13302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Beermann M, Lindeberg J, Engstrand J, Galmén K, Karlgren S, Stillström D, Nilsson H, Harbut P, Freedman J. 1000 consecutive ablation sessions in the era of computer assisted image guidance - Lessons learned. Eur J Radiol Open 2019;6:1-8. [PMID: 30547062 DOI: 10.1016/j.ejro.2018.11.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
11 Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B, Wang Y, Ye S, Ren Z. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study. J Vasc Interv Radiol 2016;27:1829-36. [PMID: 27553917 DOI: 10.1016/j.jvir.2016.06.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
12 Gong Y, Tang Y, Geng Y, Zhou Y, Yu M, Huang B, Sun Z, Tang H, Jian Z, Hou B. Comparative safety and effectiveness of ultrasound-guided radiofrequency ablation combined with preoperative three-dimensional reconstruction versus surgical resection for solitary hepatocellular carcinoma of 3-5 cm. J Cancer 2019;10:5568-74. [PMID: 31632501 DOI: 10.7150/jca.32342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
13 Seo JW. Current status and future of radiofrequency ablation for hepatocellular carcinoma. J Korean Med Assoc 2015;58:542. [DOI: 10.5124/jkma.2015.58.6.542] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Gosain R, Anwar S, Miller A, Iyer R, Mukherjee S. Interleukin-6 as a biomarker in patients with hepatobiliary cancers. J Gastrointest Oncol 2019;10:537-45. [PMID: 31183205 DOI: 10.21037/jgo.2019.01.09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Silva JP, Gorman RA, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, Gamblin TC. The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients. J Surg Oncol. 2017;116:831-840. [PMID: 28743160 DOI: 10.1002/jso.24742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
16 Wang-yuan Z, Jiang-zheng Z, Lu Y, Hao X, Hong T, Huang F, Lei J, He Z, Huang M. Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma. International Journal of Hyperthermia 2015;32:193-8. [DOI: 10.3109/02656736.2015.1099168] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
17 Yao XS, Yan D, Jiang XX, Li X, Zeng HY, Li H. Short-term outcomes of radiofrequency ablation for hepatocellular carcinoma using cone-beam computed tomography for planning and image guidance. World J Clin Cases 2021; 9(7): 1580-1591 [PMID: 33728301 DOI: 10.12998/wjcc.v9.i7.1580] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Ni Z, Wu B, Li M, Han X, Hao X, Zhang Y, Cheng W, Guo C. Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis. Ultrasound Med Biol 2022:S0301-5629(22)00365-9. [PMID: 35690523 DOI: 10.1016/j.ultrasmedbio.2022.04.217] [Reference Citation Analysis]
19 Chen Y, Zhao C, Yang Y, Xin YJ, Wang YN, Li X, Zhou X, Feng DP. Using the Controlling Nutritional Status (CONUT) Score for Evaluating Patients with Early-Stage Hepatocellular Carcinoma After Radiofrequency Ablation: A Two-Center Retrospective Study. Cardiovasc Intervent Radiol 2020;43:1294-304. [PMID: 32435833 DOI: 10.1007/s00270-020-02519-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol 2020; 26(19): 2305-2322 [PMID: 32476795 DOI: 10.3748/wjg.v26.i19.2305] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 26] [Article Influence: 16.0] [Reference Citation Analysis]
21 Zhu Z, Huang J, Liao M, Zeng Y. Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection. Jpn J Clin Oncol . [DOI: 10.1093/jjco/hyw134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 22] [Article Influence: 0.8] [Reference Citation Analysis]
22 Zheng L, Zhang CH, Lin JY, Song CL, Qi XL, Luo M. Comparative Effectiveness of Radiofrequency Ablation vs. Surgical Resection for Patients With Solitary Hepatocellular Carcinoma Smaller Than 5 cm. Front Oncol 2020;10:399. [PMID: 32296638 DOI: 10.3389/fonc.2020.00399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]